BiotechTube
CrystalsFirst

CrystalsFirst

Berlin, Germany· Est.
crystalsfirst.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

CrystalsFirst is a private, Berlin-headquartered biotech with labs in Marburg and Hamburg, specializing in a platform that merges experimental structural biology with computational AI design. Its MAGNET Discovery Engine vertically scales proprietary labware for generating high-resolution protein-ligand structures and horizontally scales AI tools to analyze and design molecules, offering a unique, integrated service to drug discovery partners. With a reported track record on over 60 structurally enabled drug targets and public testimonials from several biopharma companies, CrystalsFirst is positioned as a technology-enabled service provider in the competitive structural biology and early drug discovery space. The company appears to be in an early-revenue stage, generating income through collaborative service agreements rather than developing its own proprietary drug pipeline.

Drug DeliverySmall Molecules

Technology Platform

MAGNET Discovery Engine: A proprietary platform integrating patented high-throughput structural biology (crystallographic fragment screening, co-structure determination) with AI-powered drug design (AIDD/CADD) to accelerate small-molecule drug discovery.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

The growing demand for outsourced, high-end structural biology and integrated AI design services from biopharma companies represents a significant market opportunity.
Their unique hybrid model, which grounds AI in a proprietary stream of experimental data, addresses a key industry need for high-quality training data and could command a premium.
Expansion into new drug modalities beyond traditional small molecules could further broaden their addressable market.

Risk Factors

Revenue is dependent on the R&D spending of partner organizations, making it vulnerable to industry downturns.
The company faces intense competition from both large CROs scaling services and AI-biotechs building internal capabilities.
Maintaining technological superiority and protecting proprietary IP in a fast-evolving field is an ongoing challenge.

Competitive Landscape

CrystalsFirst competes in a fragmented landscape including large CROs with structural biology units (e.g., Charles River, Evotec), specialized structural biology service providers, and a growing number of AI-driven drug discovery companies that are increasingly adding experimental capabilities. Its key differentiator is the tight, platform-based integration of high-throughput structural biology with AI design, aiming for a faster, data-rich iterative cycle compared to more traditional or siloed service providers.

More companies in AI / Machine Learning →More companies in Germany →